marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
Kala Pharmaceuticals Balance Sheet 2011-2024 | KALA
Annual Balance Sheet Kala Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-16.4 M | -32.5 M | -12.5 M | 1.65 M | 15.7 M | -71.5 M | -95.9 M | -35.8 M | 4.04 M | - | - | - | - |
Long Term Debt |
34.2 M | 37.9 M | 78.9 M | 72.2 M | 71.2 M | 70.2 M | 12 M | 9.1 M | 7.8 M | - | - | - | - |
Long Term Debt Current |
334 K | 13 K | 711 K | 1.53 M | 1.33 M | 463 K | 6.67 M | - | - | - | - | - | - |
Total Non Current Liabilities |
40.1 M | 42.2 M | 85.2 M | 99.4 M | 99.9 M | 99 M | 12 M | 129 M | 59.6 M | - | - | - | - |
Total Current Liabilities |
8.35 M | 25.7 M | 37.4 M | 22.2 M | 24.8 M | 17 M | 14.5 M | - | - | - | - | - | - |
Total Liabilities |
48.4 M | 67.8 M | 123 M | 122 M | 125 M | 116 M | 26.5 M | 134 M | 65.1 M | - | - | - | - |
Deferred Revenue |
- | 4.19 M | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-629 M | -587 M | -542 M | -400 M | -295 M | -201 M | -134 M | -92.1 M | -59 M | - | - | - | - |
Total Assets |
55.9 M | 86.8 M | 139 M | 222 M | 154 M | 221 M | 116 M | 46.3 M | 8.45 M | - | - | - | - |
Cash and Cash Equivalents |
50.9 M | 70.5 M | 92.1 M | 77.3 M | 85.4 M | 171 M | 115 M | 45.6 M | - | - | - | - | - |
Book Value |
7.5 M | 19 M | 16.8 M | 100 M | 29.7 M | 105 M | 89.7 M | -87.8 M | -56.7 M | - | - | - | - |
Total Shareholders Equity |
7.5 M | 19 M | 16.8 M | 100 M | 29.7 M | 105 M | 89.7 M | -87.8 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Kala Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
17.2 M | 22.8 M | 28.5 M | 34.2 M | 33.9 M | 33.6 M | 3.08 M | 37.9 M | 42.6 M | 79.8 M | 79.4 M | 78.9 M | 78.5 M | 78.1 M | 72.5 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 71.2 M | 71.2 M | 71.2 M | 71.2 M | 70.2 M | 70.2 M | 70.2 M | 70.2 M | 12 M | 12 M | 12 M | 12 M | 9.1 M | 9.1 M | 9.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
23.4 M | 28.7 M | 34.5 M | 40.1 M | 39.6 M | 39.2 M | 38.5 M | 42.2 M | 46.4 M | 83.6 M | 84.1 M | 85.2 M | 105 M | 105 M | 100 M | 99.4 M | 99.4 M | 99.4 M | 99.4 M | 99.9 M | 99.9 M | 99.9 M | 99.9 M | 99 M | 99 M | 99 M | 99 M | 12 M | 12 M | 12 M | 12 M | 10.2 M | 10.2 M | 10.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
47.2 M | 47.9 M | 46.4 M | 48.4 M | 49.9 M | 49 M | 48.8 M | 67.8 M | 86.7 M | 117 M | 117 M | 123 M | 132 M | 131 M | 120 M | 122 M | 122 M | 122 M | 122 M | 125 M | 125 M | 125 M | 125 M | 116 M | 116 M | 116 M | 116 M | 26.9 M | 26.9 M | 26.9 M | 26.9 M | 15.7 M | 15.7 M | 15.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | 4.19 M | 4.19 M | 4.19 M | 3.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-660 M | -651 M | -641 M | -629 M | -621 M | -612 M | -602 M | -587 M | -574 M | -603 M | -575 M | -542 M | -495 M | -467 M | -430 M | -400 M | -400 M | -400 M | -400 M | -295 M | -295 M | -295 M | -295 M | -201 M | -201 M | -201 M | -201 M | -134 M | -134 M | -134 M | -134 M | -92.1 M | -92.1 M | -92.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
54.1 M | 61.6 M | 53 M | 55.9 M | 61.1 M | 66.5 M | 72.2 M | 86.8 M | 85.7 M | 85 M | 112 M | 139 M | 194 M | 215 M | 230 M | 222 M | 222 M | 222 M | 222 M | 154 M | 154 M | 154 M | 154 M | 221 M | 221 M | 221 M | 221 M | 117 M | 117 M | 117 M | 117 M | 46.3 M | 46.3 M | 46.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
49.2 M | 54.2 M | 48.5 M | 50.9 M | 56.1 M | 49.3 M | 63.6 M | 70.5 M | 52.4 M | 42.6 M | 65.2 M | 92.1 M | 125 M | 145 M | 128 M | 77.3 M | 77.3 M | 77.3 M | 77.3 M | 85.4 M | 85.4 M | 85.4 M | 139 M | 171 M | 171 M | 171 M | 171 M | 115 M | 122 M | 26.4 M | 115 M | 45.5 M | 51.9 M | 45.5 M | - | 5.76 M | - | - | - | 10.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
6.86 M | 13.7 M | 6.66 M | 7.5 M | 11.2 M | 17.5 M | 23.5 M | 19 M | -968 K | -31.6 M | -5.28 M | 16.8 M | 61.5 M | 84.3 M | 110 M | 100 M | 100 M | 100 M | 100 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 105 M | 105 M | 105 M | 105 M | 89.7 M | 89.7 M | 89.7 M | 89.7 M | 30.6 M | 30.6 M | 30.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
6.86 M | 13.7 M | 6.66 M | 7.5 M | 11.2 M | 17.5 M | 23.5 M | 19 M | -968 K | -31.6 M | -5.28 M | 16.8 M | 61.5 M | 84.3 M | 110 M | 100 M | 100 M | 100 M | 100 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 105 M | 105 M | 105 M | 105 M | 89.7 M | 89.7 M | 89.7 M | 89.7 M | -87.8 M | -87.8 M | -87.8 M | - | -56.7 M | - | - | - | -40.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency